Diabetes

Bacillus Calmette-Guerin Vaccination Lowers HbA1c in Type 1 Diabetes

Bacillus Calmette-Guerin Vaccination Lowers HbA1c in Type 1 Diabetes

By

Bacillus Calmette-Guerin vaccination impacted blood sugar levels in T1D by causing a systemic shift in glucose metabolism from oxidative phosphorylation to aerobic glycolysis.

Patients With Diabetes Have Higher Risk for Death From Alcohol, Accidents, Suicide

Patients With Diabetes Have Higher Risk for Death From Alcohol, Accidents, Suicide

Patients with diabetes have increased mortality due to suicide, alcohol-related causes, and accidents than those without diabetes.

Severity of Metabolic Syndrome Indicates Risk for T2D, CVD in Prediabetes Treatment

Severity of Metabolic Syndrome Indicates Risk for T2D, CVD in Prediabetes Treatment

By

Researchers analyzed how improvements in metabolic syndrome may impact the risk of developing type 2 diabetes and cardiovascular disease in patients with prediabetes.

Deep Learning Algorithm Efficiently Detects Vision-Threatening Diabetic Retinopathy

Deep Learning Algorithm Efficiently Detects Vision-Threatening Diabetic Retinopathy

By

The artificial intelligence-based deep learning algorithm shows robust performance in the detection of vision-threatening referable diabetic retinopathy.

Bone-Derived Factors in the Treatment of Diabetes

Bone-Derived Factors in the Treatment of Diabetes

By

A growing body of research highlights the important role of bone in glucose metabolism.

Periodic Fasting May Reduce Medication Use in T2D

Periodic Fasting May Reduce Medication Use in T2D

Medically supervised, therapeutic fasting regimens can help reverse type 2 diabetes (T2D) and minimize the need for pharmacological interventions.

Cost a key consideration of WHO guidelines for diabetes treatment intensification

WHO guidelines recommend selecting sulfonylureas as the single best second-line agent for Type 2 Diabetes Mellitus (T2DM) patients.

Quick Take: Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Glucagon-like peptide-1 (GLP-1) potentiates the release of insulin from pancreatic beta cells in a glucose-dependent manner.

Maternal Gluten Intake Associated With Risk for Type 1 Diabetes in Offspring

Maternal Gluten Intake Associated With Risk for Type 1 Diabetes in Offspring

By

There was an association between high maternal intake of gluten and an elevated risk for type 1 diabetes for the child.

High Levels of Prolactin in Women Inversely Linked to T2D Risk

High Levels of Prolactin in Women Inversely Linked to T2D Risk

Among U.S. women, a normally high circulating prolactin concentration is associated with a reduced risk for type 2 diabetes.

Patterns of Evidence-Based Diabetes Interventions at Local Health Departments

Patterns of Evidence-Based Diabetes Interventions at Local Health Departments

By

Improving evidence-based decision making capacity within local health departments can lead to increased offering of evidence-based interventions for diabetes management.

Domestic Refrigeration May Pose Underestimated Risk for Insulin Quality

Domestic Refrigeration May Pose Underestimated Risk for Insulin Quality

By

In many cases, insulin was exposed to temperatures outside the recommended range, especially when refrigerated.

Diabetes Associated With Elevated Risk for Arthritis, Osteoporosis

Diabetes Associated With Elevated Risk for Arthritis, Osteoporosis

By

Osteoarthritis was the most common form of arthritis in patients with diabetes but rheumatoid arthritis had the most pronounced association with diabetes.

Sitagliptin Provides Better Glycemic Control Than Dapagliflozin in T2D With Renal Impairment

Sitagliptin Provides Better Glycemic Control Than Dapagliflozin in T2D With Renal Impairment

By

Study results indicated that sitagliptin showed greater glycemic efficacy than dapagliflozin treatment.

Cardiovascular Outcomes for Albiglutide Treatment in T2D

Cardiovascular Outcomes for Albiglutide Treatment in T2D

For patients with type 2 diabetes and existing cardiovascular disease, albiglutide results in fewer cardiovascular events.

Empagliflozin Treatment Positively Impacts Life Expectancy in T2D With CVD

Empagliflozin Treatment Positively Impacts Life Expectancy in T2D With CVD

By

For this analysis, the authors used follow-up data from all 7020 patients included in the EMPA-REG OUTCOME trial to estimate the effect of empagliflozin on all-cause mortality vs placebo over the duration of a patient's lifetime.

Lixisenatide Reduces Kidney Damage in T2D With Coronary Syndrome

Lixisenatide Reduces Kidney Damage in T2D With Coronary Syndrome

For patients with type 2 diabetes and acute coronary syndrome, lixisenatide can slow or prevent damage to the kidneys.

Lorcaserin Reduces Risk for Incident Diabetes in Patients With Prediabetes

Lorcaserin Reduces Risk for Incident Diabetes in Patients With Prediabetes

By

In this new analysis, researchers looked at the long-term effects of the drug on diabetes prevention and remission in these patients.

Updated ADA, EASD Consensus Guidelines for Managing Hyperglycemia in T2D

Updated ADA, EASD Consensus Guidelines for Managing Hyperglycemia in T2D

By

Recommendations in the report highlight the importance of patient-centered decision making for glycemic management and improving diet and exercise for patients with T2D.

Positive Results for Empagliflozin in Type 1 Diabetes Trials

Positive Results for Empagliflozin in Type 1 Diabetes Trials

By

The EASE Phase 3 program included 2 double-blind, placebo-controlled trials investigating the efficacy and safety of empagliflozin as an adjunct to insulin therapy in adults with type 1 diabetes.

Elevated HbA1c After Onset of T1D Predicts Psychiatric Comorbidity

Elevated HbA1c After Onset of T1D Predicts Psychiatric Comorbidity

High average glycated hemoglobin levels during the first two years after type 1 diabetes onset predict higher risk for psychiatric diagnoses.

Better Glycemic Control With Closed-Loop Insulin Delivery

Better Glycemic Control With Closed-Loop Insulin Delivery

For patients with suboptimally controlled type 1 diabetes, day-and-night hybrid closed-loop insulin delivery improves glucose control compared with sensor-augmented pump therapy.

Safety and Mortality Outcomes Following Pediatric Growth Hormone Therapy

Safety and Mortality Outcomes Following Pediatric Growth Hormone Therapy

By

Primary cancer rates and mortality risk were no higher for pediatric patients treated with growth hormone therapy.

FDA Issues Safety Communication Regarding Pen Needle Use

FDA Issues Safety Communication Regarding Pen Needle Use

By

Standard pen needles have an outer cover and removable inner needle cover, while safety pen needles have an outer cover and a fixed inner needle shield that is not removed before an injection.

Basal Insulin Combination Therapies With Vildagliptin or Lixisenatide Equally Effective for T2D

Basal Insulin Combination Therapies With Vildagliptin or Lixisenatide Equally Effective for T2D

By

Combination therapies of basal insulin with either vildagliptin or lixisenatide are similarly effective at producing glycemic control improvements.

Genetics May Identify Type 2 Diabetes Subtypes

Genetics May Identify Type 2 Diabetes Subtypes

Clusters of type 2 diabetes loci and traits have been identified.

Many Countries Failing to Reduce Deaths From Noncommunicable Diseases

Many Countries Failing to Reduce Deaths From Noncommunicable Diseases

Many countries are falling short on targets to reduce mortality from non-communicable diseases.

Effects of Fixed-Ratio Pramlintide and Insulin on Postprandial Hyperglycemia in T1D

Effects of Fixed-Ratio Pramlintide and Insulin on Postprandial Hyperglycemia in T1D

By

Coadministration of 24 hours of fixed-ratio pramlintide and regular human insulin improves postprandial hyperglycemia and glycemic variability in patients with type 1 diabetes.

SGLT2 Inhibitors Associated With Increased Risk for Genital Infections

SGLT2 Inhibitors Associated With Increased Risk for Genital Infections

By

SGLT2 inhibitors were associated with an approximately 3-fold higher risk for developing genital infections.

Sign Up for Free e-Newsletters



CME Focus